TENX TENX

Tenax Therapeutics Stock Price

0.1395
-0.0027 (-1.9%)
Upgrade to Real-Time
Afterhours (Closed)
0.1395
Volume 2,125,988
Bid Price 0.1335
Ask Price 0.1393
News -
Day High 0.148

Low
0.08

52 Week Range

High
1.4594

Day Low 0.13
Company Name Stock Ticker Symbol Market Type
Tenax Therapeutics Inc TENX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0027 -1.9% 0.1395 19:56:00
Open Price Low Price High Price Close Price Prev Close
0.148 0.13 0.148 0.147 0.1422
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,176 2,125,988 $ 0.1362121 $ 289,585 - 0.08 - 1.4594
Last Trade Time Type Quantity Stock Price Currency
19:55:27 20 $ 0.1395 USD

Period:

Draw Mode:

Tenax Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.24M 44.70M 43.00M $ - $ - -1.93 -0.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 18.90%

more financials information »

Tenax Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TENX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.14970.15370.12780.14305452,975,392-0.0102-6.81%
1 Month0.100.19250.080.130965810,365,4970.039539.5%
3 Months0.1950.36980.080.13434454,758,353-0.0555-28.46%
6 Months0.670.690.080.14319952,335,374-0.5305-79.18%
1 Year1.161.45940.080.17135451,223,579-1.02-87.97%
3 Years1.193.680.081.281,116,645-1.05-88.28%
5 Years7.73412.630.081.62808,326-7.59-98.2%

Tenax Therapeutics Description

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.